numares HEALTH
numares HEALTH is a German diagnostics company (founded 2004) that develops the AXINON System, an FDA-cleared modular platform combining proprietary NMR spectroscopy with machine learning to deliver multi-biomarker diagnostic tests for cardiovascular, nephrology, and oncology applications to hospital laboratories and reference laboratories globally.
- Company typePrivate
- Founded2004
- HeadquartersRegensburg, Germany
- Headcount251–500
- GTM typeB2B
- OfferingSoftware
What numares HEALTH does
numares HEALTH (legal entity: numares AG) is a private German diagnostics company founded in 2004 as a spin-off of Regensburg University, headquartered in Regensburg with US offices in Houston and Boston. The company develops and commercializes the AXINON System, a modular software-based diagnostic platform that integrates proprietary Magnetic Group Signaling (MGS) technology with machine learning to enable multi-biomarker analysis from a single serum sample using nuclear magnetic resonance (NMR) spectroscopy. Its commercial product portfolio spans cardiovascular diagnostics (FDA-cleared AXINON LDL-p Test System and CE-marked AXINON lipoFIT), nephrology (CE-marked AXINON GFR(NMR) and AXINON renalTX-SCORE for transplant rejection), and oncology in development (AXINON HCC(NMR) for liver cancer), with additional pipeline assets under exclusive license from Oxford University for multiple sclerosis biomarkers.
The company sells the AXINON System as a B2B enterprise platform to qualified hospital laboratories, transplant centers, cardiology practices, and reference laboratories that already operate qualified 600 MHz NMR spectrometers. Revenue is generated through a combination of one-time system hardware and software license sales, recurring reagent kit and consumable purchases (e.g., AXINON serum kits), modular test application licenses, and annual service contracts. Go-to-market combines direct enterprise sales with channel partnerships for international expansion, including a recent BioD Medica distribution agreement covering Malaysia and Singapore following Malaysia regulatory approval in December 2025.
numares has accumulated over €46 million in disclosed funding across multiple rounds led by Bayern Kapital, KfW, SHS Capital, and most recently a €20 million facility from the European Investment Bank in December 2022. The company operates with 251-500 employees, holds EN ISO 13485:2016 certification for IVD manufacturing, maintains multi-jurisdiction regulatory approvals (FDA, CE-IVD, Malaysia), and has clinical research collaborations with Mayo Clinic and University Hospital Regensburg supporting ongoing biomarker validation.
numares HEALTH firmographics
Firmographics- Name
- numares HEALTH
- Legal name
- numares AG
- Website
- https://numares.com
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- numares HEALTH is a German diagnostics company (founded 2004) that develops the AXINON System, an FDA-cleared modular platform combining proprietary NMR spectroscopy with machine learning to deliver multi-biomarker diagnostic tests for cardiovascular, nephrology, and oncology applications to hospital laboratories and reference laboratories globally.
- Ownership category
- akta.pro rank
numares HEALTH industry classification
Industry- Product category
- In Vitro Diagnostics (IVD)
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Medical and Diagnostic Laboratories (6215)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)
- akta.pro secondary industry
- Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)
Keywords
Where numares HEALTH is headquartered
LocationHeadquarters
- HQ city
- Regensburg
- HQ country
- Germany
- HQ region
- Europe
Offices3 records
Markets served
numares HEALTH business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- AXINON System Hardware and Software: Sale of the AXINON System including NMR integration software, test-specific modules, and installation/qualification services. The system requires a qualified 600 MHz NMR spectrometer with specific specifications.
- Reagent Kits and Consumables: Recurring revenue from AXINON reagent kits (serum and urine), NMR tubes, and other consumables required for each test run. Examples include AXINON lipoFIT-S100 serum kit.
- Test Licenses: Modular platform supports multiple simultaneous tests on the same system. Additional test applications can be installed as they receive regulatory approval, generating additional license revenue.
- Service Contracts and Technical Support: Annual service contracts and technical support including maintenance guidance, troubleshooting, and system qualification services.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels7 records
numares HEALTH product offering
Product offeringCore offering
numares HEALTH develops and markets the AXINON System, a modular software-based platform that combines nuclear magnetic resonance (NMR) spectroscopy with proprietary AI/ML algorithms to quantify multiple biomarkers from a single serum sample. The company sells in vitro diagnostic tests for cardiovascular risk assessment (AXINON LDL-p Test System, AXINON lipoFIT), kidney function and transplant rejection monitoring (AXINON GFR(NMR), AXINON renalTX-SCORE U100), and liver cancer detection (AXINON HCC(NMR)), together with associated reagent kits, consumables, and service contracts.
Product overview
numares HEALTH develops the AXINON System as its core modular, software-based NMR diagnostic platform for precision diagnostics. The platform is designed to support multiple diagnostic tests including AXINON lipoFIT (cardiovascular risk assessment), AXINON GFR (kidney function), AXINON HCC (liver cancer detection in development), and AXINON LDL-p (FDA-cleared cardiovascular test). The system uses proprietary Magnetic Group Signaling (MGS) technology to standardize NMR measurements and machine learning algorithms for metabolite analysis. The company focuses on multi-biomarker diagnostics for chronic kidney, liver, and cardiac diseases related to metabolic dysfunction.
Differentiator
Problem solved
Functional benefit
Brands
- AXINON® System: FDA-cleared core technology platform incorporating diagnostic testing algorithms into nuclear magnetic resonance (NMR) spectroscopy for clinical diagnostics
- AXINON® lipoFIT®
- AXINON® LDL-p Test System
- AXINON® GFR (NMR)
- AXINON® HCC(NMR)
- Magnetic Group Signaling (MGS®)
Products and services
- AXINON System FDA-cleared modular software-based NMR diagnostic platform that incorporates diagnostic testing algorithms into nuclear magnetic resonance spectroscopy for clinical laboratories. It is the first modular software-based system for clinical diagnostics, supporting multiple tests for cardiovascular, nephrology, and oncology applications.
- AXINON LDL-p Test System FDA-cleared cardiovascular diagnostic test that measures lipoproteins and provides more detailed information about cardiac function than standard LDL-C measurement, for patients at risk of cardiovascular disease.
- AXINON lipoFIT Cardiovascular risk assessment test providing 16 parameters from serum including lipoprotein subclasses, available as a CE-labeled in vitro diagnostic product in the EU.
- AXINON GFR (NMR) Kidney function assay combining novel biomarkers (valine and myo-inositol) with creatinine and cystatin C using NMR spectroscopy, available as a CE-labeled in vitro diagnostic product in the EU.
- AXINON HCC (NMR) Liver cancer detection test (hepatocellular carcinoma) and NASH staging/diagnosis test using serum biomarker testing via NMR spectroscopy. Currently in development.
- AXINON renalTX-SCORE U100 Renal allograft rejection diagnostic test for urine samples, achieving AUC 0.72 (95% CI 0.62-0.82) for detecting acute kidney transplant rejection during the first 14 days after transplantation in living-donor recipients.
Quantifiable outcome
- AUC 0.72 (95% CI 0.62-0.82) for detecting acute kidney transplant rejection during first 14 days after living-donor transplantation
- +2 more outcomes
Companies that use numares HEALTH
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
numares HEALTH technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
numares HEALTH partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and major.
- University Hospital RegensburgcoreClinical research partnership conducting biomarker validation studies for kidney transplant rejection detection. The study published in Frontiers in Medicine analyzed 682 urine samples from 109 recipients demonstrating test efficacy.
- BioD MedicamajorDistribution partner for Malaysia and Singapore. Secured first contract win for AXINON LDLp Test System in ASEAN region following regulatory approval in Malaysia. Partner handles local sales and distribution.
- Mayo CliniccoreCollaboration for improved diagnostic tests leveraging Mayo Clinic's clinical expertise and research capabilities alongside numares' NMR metabolomics technology. The partnership aims to strengthen diagnostic test development and validation.
- Oxford UniversitycoreExclusive licensing agreement for novel multi-marker diagnostics for multiple sclerosis. Oxford's research on MS biomarkers combined with numares' NMR platform for diagnostic test development.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
numares HEALTH competitors and assessment
Company assessmentBroad incumbents
- Roche Diagnostics: Division of Roche operating one of the world's largest IVD businesses, including cardiac and renal marker assays. Comparable because it competes for the same clinical lab budgets and provides the standard-of-care lipid and kidney function tests against which numares' NMR-based alternatives must demonstrate superiority.
- Siemens Healthineers: Global medical technology company with a broad in vitro diagnostics portfolio including clinical chemistry, immunoassays, and laboratory automation. Comparable because it serves the same hospital and reference lab customers for cardiovascular and renal diagnostics, but through routine chemistry rather than NMR metabolomics.
- Bruker: Leading manufacturer of NMR spectrometers and scientific instruments used in research and clinical settings. Comparable as the dominant NMR instrumentation supplier whose hardware underpins the AXINON System and whose installed base represents a potential partner or competitor depending on go-to-market choices.
- Labcorp: Major clinical diagnostics laboratory that acquired Liposcience (NMR LipoProfile) and operates one of the most advanced NMR-based cardiovascular testing services. Comparable because it offers an NMR-based lipoprotein subclass test directly competing with AXINON LDL-p and lipoFIT, but within a much broader diagnostics portfolio.
Emerging players
- Oxford BioDynamics: UK-based diagnostics company spun out of Oxford University that develops multi-biomarker tests using proprietary epigenetics platform. Comparable because of the Oxford University heritage and biomarker-based test development model targeting chronic disease, sharing the Oxford IP licensing dynamics.
- Meso Scale Diagnostics: US diagnostics company providing multiplex biomarker assay platforms for research and clinical customers. Comparable as an emerging biomarker platform company serving translational research and specialty clinical diagnostics markets with multi-analyte testing, sharing a similar B2B lab customer profile.
- Quanterix: US diagnostics company offering ultra-sensitive biomarker detection technology (Simoa) for neurology, oncology, and inflammatory disease applications. Comparable as an emerging precision diagnostics platform company whose success similarly depends on clinical adoption of novel biomarker assays over standard lab tests.
- C2N Diagnostics: US diagnostics company developing blood-based biomarker tests for neurodegenerative diseases (notably Alzheimer's PrecivityAD). Comparable as an emerging precision diagnostics company leveraging proprietary biomarker assays for chronic disease, sharing a similar go-to-market approach targeting specialty clinical customers.
Direct peers
- Nightingale Health: Finnish health technology company that uses NMR spectroscopy to analyze blood biomarkers for chronic disease risk assessment. Most directly comparable peer because it applies the same NMR metabolomics approach to clinical diagnostics targeting cardiovascular and metabolic disease, mirroring numares' AXINON platform strategy.
- Metabolon: US-based metabolomics company offering biomarker discovery and analytical services for pharmaceutical, academic, and clinical research customers. Comparable because it operates in the same NMR/mass-spec metabolomics space and serves overlapping translational research and clinical development customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
numares HEALTH social profiles
Digital presencenumares HEALTH compliance and trust
Trust signalCompliance2 records
numares HEALTH financial estimates
Financial estimateRevenue estimate
Valuation estimate
numares HEALTH leadership team
Management profileNumber of profiles
Profiles10 records
numares HEALTH funding detail
Funding detailFunding overview
Funding rounds6 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
numares HEALTH M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about numares HEALTH
What does numares HEALTH do?
numares HEALTH develops and markets the AXINON System, a modular software-based platform that combines nuclear magnetic resonance (NMR) spectroscopy with proprietary AI/ML algorithms to quantify multiple biomarkers from a single serum sample. The company sells in vitro diagnostic tests for cardiovascular risk assessment (AXINON LDL-p Test System, AXINON lipoFIT), kidney function and transplant rejection monitoring (AXINON GFR(NMR), AXINON renalTX-SCORE U100), and liver cancer detection (AXINON HCC(NMR)), together with associated reagent kits, consumables, and service contracts.
Is numares HEALTH a public or private company?
numares HEALTH is a private company. It is classified as venture growth investor backed and is currently operating.
When was numares HEALTH founded?
numares HEALTH was founded in 2004. It employs 251 to 500 people.
Where is numares HEALTH based?
numares HEALTH is headquartered in Regensburg, Germany, in the Europe region.
How does numares HEALTH make money?
Four revenue lines are on record. AXINON System Hardware and Software is the primary driver. The others are reagent Kits and Consumables, test Licenses and service Contracts and Technical Support.
Who are numares HEALTH's main competitors?
Broad incumbents on record are Roche Diagnostics, Siemens Healthineers, Bruker and Labcorp. Emerging players are Oxford BioDynamics, Meso Scale Diagnostics, Quanterix and C2N Diagnostics. Direct peers are Nightingale Health and Metabolon.
Does numares HEALTH have an API?
No public API is recorded for numares HEALTH.
What industry is numares HEALTH in?
numares HEALTH's product category is In Vitro Diagnostics (IVD). Its primary akta.pro industry code is HLAAAMAJ, Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics), with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 334516 and its SIC code is 2835.